Are you over 18 and want to see adult content?
More Annotations
A complete backup of www.www.abcoeur.com
Are you over 18 and want to see adult content?
A complete backup of beautifulagony.com
Are you over 18 and want to see adult content?
A complete backup of www.www.imagefap.com
Are you over 18 and want to see adult content?
A complete backup of www.www.yournnpic.com
Are you over 18 and want to see adult content?
A complete backup of www.xhamster.desi
Are you over 18 and want to see adult content?
A complete backup of amateuralbum.net
Are you over 18 and want to see adult content?
A complete backup of thefappening.pro
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of extremweather.de
Are you over 18 and want to see adult content?
A complete backup of lagrantfoundation.org
Are you over 18 and want to see adult content?
A complete backup of novaxguitars.com
Are you over 18 and want to see adult content?
A complete backup of ianstormtaylor.com
Are you over 18 and want to see adult content?
Text
(MicroVention)
TERUMO REPORTS
"Terumo Information" for investors. Terumo Reports are available onthis page.
NORTH AMERICA
Japan; North America; South America; EMEA; Greater China; Asia; Terumo has been doing business in North America for nearly half a century. Terumo America Inc. (now Terumo Americas Holdings) was founded in 1971, and since then the Terumo business has grown much larger andmore diverse.
VASCULAR GRAFTS DIVISION (TERUMO AORTIC) Terumo Aortic, a new brand formed from two leading companies in the treatment of aortic disease: Bolton Medical of the United States and Vascutek of the United Kingdom, as part of the Japan-based global healthcare company Terumo. TERUMO LAUNCHES HEARTSHEET®: A GLOBAL FIRST CELLULAR AND June 6, 2016. Terumo Corporation (Headquarters: Tokyo, Japan; President and CEO: Yutaro Shintaku) announced today that in late May it commenced sales of HeartSheet - a global first cellular and tissue-based product designed for the treatment of heart failure.. HeartSheet is designed for treating severe heart failure caused by chronic ischemic heart disease.GREATER CHINA
The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. JAPAN | GLOBAL NETWORK | TERUMO GLOBAL The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. TERUMO GLOBAL WEBSITEBUSINESS OVERVIEW TOPTIS DIVISION(TERUMO INTERVENTIONAL SYSTEMS) This is the Terumo Group global website; Terumo corporate information, business introductions, and IR, sustainability, and Global Network information are available here. INVESTORS | TERUMO GLOBALTERUMO REPORTFINANCIAL INFORMATION Financial Results for the Fiscal Year Ended 3/2021. May 12, 2021 TERUMO 100TH ANNIVERSARY WEBSITE Terumo 100th Anniversary Website. 100 years have passed since Terumo’s foundation. Its debut product, the domestically produced safe, high-quality thermometer, was launched on the market in the hope of delivering it to as many people as possible. Under the corporate mission; Contributing to Society through Healthcare, we have since SITE MAP | TERUMO GLOBAL This page is the Terumo website Site Map. Business Overview. TIS Division (Terumo Interventional Systems) Neurovascular Division(MicroVention)
TERUMO REPORTS
"Terumo Information" for investors. Terumo Reports are available onthis page.
NORTH AMERICA
Japan; North America; South America; EMEA; Greater China; Asia; Terumo has been doing business in North America for nearly half a century. Terumo America Inc. (now Terumo Americas Holdings) was founded in 1971, and since then the Terumo business has grown much larger andmore diverse.
VASCULAR GRAFTS DIVISION (TERUMO AORTIC) Terumo Aortic, a new brand formed from two leading companies in the treatment of aortic disease: Bolton Medical of the United States and Vascutek of the United Kingdom, as part of the Japan-based global healthcare company Terumo. TERUMO LAUNCHES HEARTSHEET®: A GLOBAL FIRST CELLULAR AND June 6, 2016. Terumo Corporation (Headquarters: Tokyo, Japan; President and CEO: Yutaro Shintaku) announced today that in late May it commenced sales of HeartSheet - a global first cellular and tissue-based product designed for the treatment of heart failure.. HeartSheet is designed for treating severe heart failure caused by chronic ischemic heart disease.GREATER CHINA
The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. JAPAN | GLOBAL NETWORK | TERUMO GLOBAL The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. SITE MAP | TERUMO GLOBAL This page is the Terumo website Site Map. Business Overview. TIS Division (Terumo Interventional Systems) Neurovascular Division(MicroVention)
HISTORY | ABOUT TERUMO | TERUMO GLOBAL History. Terumo Corporation was founded in 1921 by several scientists and doctors, including Dr. Shibasaburo Kitasato, to produce clinical thermometers in Japan. These vital medical devices had previously been imported, until they were cut off as a consequence of World War I. The lifelong spirit of Dr. Kitasato, whose achievements received VASCULAR GRAFTS DIVISION (TERUMO AORTIC) Terumo Aortic, a new brand formed from two leading companies in the treatment of aortic disease: Bolton Medical of the United States and Vascutek of the United Kingdom, as part of the Japan-based global healthcare company Terumo. DIRECTORS AND EXECUTIVE OFFICERS Directors. Takayoshi Mimura. Chairman of the Board. Shinjiro Sato. President and CEO. Toshiaki Takagi. Director and Senior ManagingExecutive Officer.
TERUMO SIGNS A DEFINITIVE AGREEMENT TO ACQUIRE ALL ASSETS February 24, 2021. TOKYO, JAPAN - February 24, 2021 - Terumo Corporation (TSE: 4543), a global leader in medical technology, has signed a definitive agreement to acquire all assets of Health Outcomes Sciences, Inc. (HOS).HOS specializes in predictive analytics and clinical decision support that enable healthcare organizations to deliver personalized, predictive insights at the point of care TERUMO TO ESTABLISH 'DX PROMOTION DEPARTMENT' FOR February 4, 2021. TOKYO, JAPAN - February 4, 2021 - Terumo Corporation (TSE: 4543) today announced that it will establish the 'DX Promotion Department' on April 1, 2021. TERUMO LAUNCHES NEW SURGICAL SEALANT AQUABRID® IN EMEA AQUABRID® is a fully synthetic surgical sealant developed for aortic surgical procedures. When in contact with water, it reacts and forms a strong, elastic layer within three to five minutes. This makes it ideal for use in wet conditions -- AQUABRID® can be applied directly to wet natural and/or artificial tissue (e.g., an aortic graft). 5,8. PROCUREMENT ACTIVITY Procurement Activity. Terumo strives to be a reliable healthcare company worldwide and promote corporate activities under the group mission of “Contributing to Society through Healthcare” and the “Terumo Group Code of Conduct.”. The “Terumo Group Code of Conduct” defines the principles of behavior to follow so that allassociates
#06 TERUMO BAY AREA INNOVATION LAB A PLACE TO CREATE NEW Informing Terumo Technology, and this page introduces the story #06 Terumo Bay Area Innovation Lab A place to create new value. JAPAN | GLOBAL NETWORK | TERUMO GLOBAL The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. TERUMO GLOBAL WEBSITEBUSINESS OVERVIEW TOPTIS DIVISION(TERUMO INTERVENTIONAL SYSTEMS) This is the Terumo Group global website; Terumo corporate information, business introductions, and IR, sustainability, and Global Network information are available here. INVESTORS | TERUMO GLOBALTERUMO REPORTFINANCIAL INFORMATION Financial Results for the Fiscal Year Ended 3/2021. May 12, 2021TERUMO REPORTS
"Terumo Information" for investors. Terumo Reports are available onthis page.
VASCULAR GRAFTS DIVISION (TERUMO AORTIC) Terumo Aortic, a new brand formed from two leading companies in the treatment of aortic disease: Bolton Medical of the United States and Vascutek of the United Kingdom, as part of the Japan-based global healthcare company Terumo. FINANCIAL STATEMENTS Financial Results for FYE 3/2020 (1.6 MB) Financial Results for FYE 3/2020 : Reference (163.9 KB) 3rd Quarter Financial Results for FYE 3/2020 (1.2 MB) 3rd Quarter Financial Results for FYE 3/2020 : Reference (128.3 KB) 1st Half Financial Results for FYE 3/2020 (494.6KB)
#06 TERUMO BAY AREA INNOVATION LAB A PLACE TO CREATE NEW Informing Terumo Technology, and this page introduces the story #06 Terumo Bay Area Innovation Lab A place to create new value. TERUMO LAUNCHES HEARTSHEET®: A GLOBAL FIRST CELLULAR AND June 6, 2016. Terumo Corporation (Headquarters: Tokyo, Japan; President and CEO: Yutaro Shintaku) announced today that in late May it commenced sales of HeartSheet - a global first cellular and tissue-based product designed for the treatment of heart failure.. HeartSheet is designed for treating severe heart failure caused by chronic ischemic heart disease. TERUMO AORTIC ANNOUNCES US FDA APPROVAL FOR TREOTERUMO AORTICTERUMO AORTIC GRAFTSTERUMO GRAFT MRI SAFETY Terumo Aortic today announced that the US Food and Drug Administration (FDA) has granted approval of the TREO™ Abdominal Aortic Stent-Graft System for sale in the United States for the treatment of patients with abdominal aortic aneurysms (AAA). TREO is the only device commercially available for endovascular aneurysm repair (EVAR) withdual
JAPAN | GLOBAL NETWORK | TERUMO GLOBAL The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services.GREATER CHINA
The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. TERUMO GLOBAL WEBSITEBUSINESS OVERVIEW TOPTIS DIVISION(TERUMO INTERVENTIONAL SYSTEMS) This is the Terumo Group global website; Terumo corporate information, business introductions, and IR, sustainability, and Global Network information are available here. INVESTORS | TERUMO GLOBALTERUMO REPORTFINANCIAL INFORMATION Financial Results for the Fiscal Year Ended 3/2021. May 12, 2021TERUMO REPORTS
"Terumo Information" for investors. Terumo Reports are available onthis page.
VASCULAR GRAFTS DIVISION (TERUMO AORTIC) Terumo Aortic, a new brand formed from two leading companies in the treatment of aortic disease: Bolton Medical of the United States and Vascutek of the United Kingdom, as part of the Japan-based global healthcare company Terumo. FINANCIAL STATEMENTS Financial Results for FYE 3/2020 (1.6 MB) Financial Results for FYE 3/2020 : Reference (163.9 KB) 3rd Quarter Financial Results for FYE 3/2020 (1.2 MB) 3rd Quarter Financial Results for FYE 3/2020 : Reference (128.3 KB) 1st Half Financial Results for FYE 3/2020 (494.6KB)
#06 TERUMO BAY AREA INNOVATION LAB A PLACE TO CREATE NEW Informing Terumo Technology, and this page introduces the story #06 Terumo Bay Area Innovation Lab A place to create new value. TERUMO LAUNCHES HEARTSHEET®: A GLOBAL FIRST CELLULAR AND June 6, 2016. Terumo Corporation (Headquarters: Tokyo, Japan; President and CEO: Yutaro Shintaku) announced today that in late May it commenced sales of HeartSheet - a global first cellular and tissue-based product designed for the treatment of heart failure.. HeartSheet is designed for treating severe heart failure caused by chronic ischemic heart disease. TERUMO AORTIC ANNOUNCES US FDA APPROVAL FOR TREOTERUMO AORTICTERUMO AORTIC GRAFTSTERUMO GRAFT MRI SAFETY Terumo Aortic today announced that the US Food and Drug Administration (FDA) has granted approval of the TREO™ Abdominal Aortic Stent-Graft System for sale in the United States for the treatment of patients with abdominal aortic aneurysms (AAA). TREO is the only device commercially available for endovascular aneurysm repair (EVAR) withdual
JAPAN | GLOBAL NETWORK | TERUMO GLOBAL The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services.GREATER CHINA
The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. SITE MAP | TERUMO GLOBAL This page is the Terumo website Site Map. Business Overview. TIS Division (Terumo Interventional Systems) Neurovascular Division(MicroVention)
TERUMO 100TH ANNIVERSARY WEBSITE Terumo 100th Anniversary Website. 100 years have passed since Terumo’s foundation. Its debut product, the domestically produced safe, high-quality thermometer, was launched on the market in the hope of delivering it to as many people as possible. Under the corporate mission; Contributing to Society through Healthcare, we have sinceGLOBAL NETWORK
The regulatory approval status and availability of Terumo Group products differs by country and region.You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services.PRESENTATIONS
November 5, 2020. Presentation Material. "Alliance Business: Develop a Growth Driver by Infusing Core Technologies with a New Business Model" (674.0 KB) "Financial Results for the First Half of FYE 3/2021" (654.2 KB) "Financial Results for the First Half of FYE 3/2021"(with note) (3.9 MB) Additional Information. Corporate Data File (476.4KB)
HOSPITAL SYSTEMS DIVISION The Hospital Systems Division provides medical devices and pharmaceuticals that are used in a variety of medical settings, including ICUs, general wards, operating rooms, and patients' homes; along with training programs for medical professionals who use the products. Populations are aging, and that means more people requiremedical care.
NORTH AMERICA
Japan; North America; South America; EMEA; Greater China; Asia; Terumo has been doing business in North America for nearly half a century. Terumo America Inc. (now Terumo Americas Holdings) was founded in 1971, and since then the Terumo business has grown much larger andmore diverse.
QUARTERLY RESULTS
"Terumo Information" for investors. Quarterly Results is available onthis page.
#02 CONTINUOUSLY INNOVATING FIRST-IN-CLASS TECHNOLOGY TO Reducing burden on patient blood during cardiovascular surgery by improving oxygenators. Terumo provides heart-lung machines that are used to circulate blood through the body in place of the heart during cardiovascular surgery, and hollow-fiber oxygenators that exchange oxygen for carbon dioxide in place of the lungs.GREATER CHINA
The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. TERUMO COMPLETES ACQUISITION OF CHINA-BASED ESSEN January 7, 2019. TOKYO, JAPAN - January 7, 2019 - Terumo Corporation (TSE: 4543) today announced that it completed its acquisition of Essen Technology (Beijing) Co., Ltd., a Chinese medical device company, onDecember 29, 2018.
TERUMO GLOBAL WEBSITEBUSINESS OVERVIEW TOPTIS DIVISION(TERUMO INTERVENTIONAL SYSTEMS) This is the Terumo Group global website; Terumo corporate information, business introductions, and IR, sustainability, and Global Network information are available here. INVESTORS | TERUMO GLOBALTERUMO REPORTFINANCIAL INFORMATION Financial Results for the Fiscal Year Ended 3/2021. May 12, 2021TERUMO REPORTS
"Terumo Information" for investors. Terumo Reports are available onthis page.
VASCULAR GRAFTS DIVISION (TERUMO AORTIC) Terumo Aortic, a new brand formed from two leading companies in the treatment of aortic disease: Bolton Medical of the United States and Vascutek of the United Kingdom, as part of the Japan-based global healthcare company Terumo. FINANCIAL STATEMENTS Financial Results for FYE 3/2020 (1.6 MB) Financial Results for FYE 3/2020 : Reference (163.9 KB) 3rd Quarter Financial Results for FYE 3/2020 (1.2 MB) 3rd Quarter Financial Results for FYE 3/2020 : Reference (128.3 KB) 1st Half Financial Results for FYE 3/2020 (494.6KB)
#06 TERUMO BAY AREA INNOVATION LAB A PLACE TO CREATE NEW Informing Terumo Technology, and this page introduces the story #06 Terumo Bay Area Innovation Lab A place to create new value. TERUMO LAUNCHES HEARTSHEET®: A GLOBAL FIRST CELLULAR AND June 6, 2016. Terumo Corporation (Headquarters: Tokyo, Japan; President and CEO: Yutaro Shintaku) announced today that in late May it commenced sales of HeartSheet - a global first cellular and tissue-based product designed for the treatment of heart failure.. HeartSheet is designed for treating severe heart failure caused by chronic ischemic heart disease. TERUMO AORTIC ANNOUNCES US FDA APPROVAL FOR TREOTERUMO AORTICTERUMO AORTIC GRAFTSTERUMO GRAFT MRI SAFETY Terumo Aortic today announced that the US Food and Drug Administration (FDA) has granted approval of the TREO™ Abdominal Aortic Stent-Graft System for sale in the United States for the treatment of patients with abdominal aortic aneurysms (AAA). TREO is the only device commercially available for endovascular aneurysm repair (EVAR) withdual
JAPAN | GLOBAL NETWORK | TERUMO GLOBAL The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services.GREATER CHINA
The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. TERUMO GLOBAL WEBSITEBUSINESS OVERVIEW TOPTIS DIVISION(TERUMO INTERVENTIONAL SYSTEMS) This is the Terumo Group global website; Terumo corporate information, business introductions, and IR, sustainability, and Global Network information are available here. INVESTORS | TERUMO GLOBALTERUMO REPORTFINANCIAL INFORMATION Financial Results for the Fiscal Year Ended 3/2021. May 12, 2021TERUMO REPORTS
"Terumo Information" for investors. Terumo Reports are available onthis page.
VASCULAR GRAFTS DIVISION (TERUMO AORTIC) Terumo Aortic, a new brand formed from two leading companies in the treatment of aortic disease: Bolton Medical of the United States and Vascutek of the United Kingdom, as part of the Japan-based global healthcare company Terumo. FINANCIAL STATEMENTS Financial Results for FYE 3/2020 (1.6 MB) Financial Results for FYE 3/2020 : Reference (163.9 KB) 3rd Quarter Financial Results for FYE 3/2020 (1.2 MB) 3rd Quarter Financial Results for FYE 3/2020 : Reference (128.3 KB) 1st Half Financial Results for FYE 3/2020 (494.6KB)
#06 TERUMO BAY AREA INNOVATION LAB A PLACE TO CREATE NEW Informing Terumo Technology, and this page introduces the story #06 Terumo Bay Area Innovation Lab A place to create new value. TERUMO LAUNCHES HEARTSHEET®: A GLOBAL FIRST CELLULAR AND June 6, 2016. Terumo Corporation (Headquarters: Tokyo, Japan; President and CEO: Yutaro Shintaku) announced today that in late May it commenced sales of HeartSheet - a global first cellular and tissue-based product designed for the treatment of heart failure.. HeartSheet is designed for treating severe heart failure caused by chronic ischemic heart disease. TERUMO AORTIC ANNOUNCES US FDA APPROVAL FOR TREOTERUMO AORTICTERUMO AORTIC GRAFTSTERUMO GRAFT MRI SAFETY Terumo Aortic today announced that the US Food and Drug Administration (FDA) has granted approval of the TREO™ Abdominal Aortic Stent-Graft System for sale in the United States for the treatment of patients with abdominal aortic aneurysms (AAA). TREO is the only device commercially available for endovascular aneurysm repair (EVAR) withdual
JAPAN | GLOBAL NETWORK | TERUMO GLOBAL The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services.GREATER CHINA
The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. SITE MAP | TERUMO GLOBAL This page is the Terumo website Site Map. Business Overview. TIS Division (Terumo Interventional Systems) Neurovascular Division(MicroVention)
TERUMO 100TH ANNIVERSARY WEBSITE Terumo 100th Anniversary Website. 100 years have passed since Terumo’s foundation. Its debut product, the domestically produced safe, high-quality thermometer, was launched on the market in the hope of delivering it to as many people as possible. Under the corporate mission; Contributing to Society through Healthcare, we have sinceGLOBAL NETWORK
The regulatory approval status and availability of Terumo Group products differs by country and region.You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services.PRESENTATIONS
November 5, 2020. Presentation Material. "Alliance Business: Develop a Growth Driver by Infusing Core Technologies with a New Business Model" (674.0 KB) "Financial Results for the First Half of FYE 3/2021" (654.2 KB) "Financial Results for the First Half of FYE 3/2021"(with note) (3.9 MB) Additional Information. Corporate Data File (476.4KB)
HOSPITAL SYSTEMS DIVISION The Hospital Systems Division provides medical devices and pharmaceuticals that are used in a variety of medical settings, including ICUs, general wards, operating rooms, and patients' homes; along with training programs for medical professionals who use the products. Populations are aging, and that means more people requiremedical care.
NORTH AMERICA
Japan; North America; South America; EMEA; Greater China; Asia; Terumo has been doing business in North America for nearly half a century. Terumo America Inc. (now Terumo Americas Holdings) was founded in 1971, and since then the Terumo business has grown much larger andmore diverse.
QUARTERLY RESULTS
"Terumo Information" for investors. Quarterly Results is available onthis page.
#02 CONTINUOUSLY INNOVATING FIRST-IN-CLASS TECHNOLOGY TO Reducing burden on patient blood during cardiovascular surgery by improving oxygenators. Terumo provides heart-lung machines that are used to circulate blood through the body in place of the heart during cardiovascular surgery, and hollow-fiber oxygenators that exchange oxygen for carbon dioxide in place of the lungs.GREATER CHINA
The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. TERUMO COMPLETES ACQUISITION OF CHINA-BASED ESSEN January 7, 2019. TOKYO, JAPAN - January 7, 2019 - Terumo Corporation (TSE: 4543) today announced that it completed its acquisition of Essen Technology (Beijing) Co., Ltd., a Chinese medical device company, onDecember 29, 2018.
TERUMO GLOBAL WEBSITEBUSINESS OVERVIEW TOPTIS DIVISION(TERUMO INTERVENTIONAL SYSTEMS) This is the Terumo Group global website; Terumo corporate information, business introductions, and IR, sustainability, and Global Network information are available here. INVESTORS | TERUMO GLOBALTERUMO REPORTFINANCIAL INFORMATION Financial Results for the Fiscal Year Ended 3/2021. May 12, 2021TERUMO REPORTS
"Terumo Information" for investors. Terumo Reports are available onthis page.
VASCULAR GRAFTS DIVISION (TERUMO AORTIC) Terumo Aortic, a new brand formed from two leading companies in the treatment of aortic disease: Bolton Medical of the United States and Vascutek of the United Kingdom, as part of the Japan-based global healthcare company Terumo. #06 TERUMO BAY AREA INNOVATION LAB A PLACE TO CREATE NEW Informing Terumo Technology, and this page introduces the story #06 Terumo Bay Area Innovation Lab A place to create new value. FINANCIAL STATEMENTS "Terumo Information" for investors. Terumo IR materials are availableon this page.
TERUMO AORTIC ANNOUNCES US FDA APPROVAL FOR TREOTERUMO AORTICTERUMO AORTIC GRAFTSTERUMO GRAFT MRI SAFETY May 5, 2020. Terumo Aortic today announced that the US Food and Drug Administration (FDA) has granted approval of the TREO™ Abdominal Aortic Stent-Graft System for sale in the United States for the treatment of patients with abdominal aortic aneurysms (AAA). TERUMO LAUNCHES HEARTSHEET®: A GLOBAL FIRST CELLULAR AND June 6, 2016. Terumo Corporation (Headquarters: Tokyo, Japan; President and CEO: Yutaro Shintaku) announced today that in late May it commenced sales of HeartSheet - a global first cellular and tissue-based product designed for the treatment of heart failure.. HeartSheet is designed for treating severe heart failure caused by chronic ischemic heart disease. JAPAN | GLOBAL NETWORK | TERUMO GLOBAL The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services.GREATER CHINA
The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. TERUMO GLOBAL WEBSITEBUSINESS OVERVIEW TOPTIS DIVISION(TERUMO INTERVENTIONAL SYSTEMS) This is the Terumo Group global website; Terumo corporate information, business introductions, and IR, sustainability, and Global Network information are available here. INVESTORS | TERUMO GLOBALTERUMO REPORTFINANCIAL INFORMATION Financial Results for the Fiscal Year Ended 3/2021. May 12, 2021TERUMO REPORTS
"Terumo Information" for investors. Terumo Reports are available onthis page.
VASCULAR GRAFTS DIVISION (TERUMO AORTIC) Terumo Aortic, a new brand formed from two leading companies in the treatment of aortic disease: Bolton Medical of the United States and Vascutek of the United Kingdom, as part of the Japan-based global healthcare company Terumo. #06 TERUMO BAY AREA INNOVATION LAB A PLACE TO CREATE NEW Informing Terumo Technology, and this page introduces the story #06 Terumo Bay Area Innovation Lab A place to create new value. FINANCIAL STATEMENTS "Terumo Information" for investors. Terumo IR materials are availableon this page.
TERUMO AORTIC ANNOUNCES US FDA APPROVAL FOR TREOTERUMO AORTICTERUMO AORTIC GRAFTSTERUMO GRAFT MRI SAFETY May 5, 2020. Terumo Aortic today announced that the US Food and Drug Administration (FDA) has granted approval of the TREO™ Abdominal Aortic Stent-Graft System for sale in the United States for the treatment of patients with abdominal aortic aneurysms (AAA). TERUMO LAUNCHES HEARTSHEET®: A GLOBAL FIRST CELLULAR AND June 6, 2016. Terumo Corporation (Headquarters: Tokyo, Japan; President and CEO: Yutaro Shintaku) announced today that in late May it commenced sales of HeartSheet - a global first cellular and tissue-based product designed for the treatment of heart failure.. HeartSheet is designed for treating severe heart failure caused by chronic ischemic heart disease. JAPAN | GLOBAL NETWORK | TERUMO GLOBAL The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services.GREATER CHINA
The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. TERUMO 100TH ANNIVERSARY WEBSITE Terumo celebrates its 100th anniversary in 2021. This website covers 100 years of Terumo’s history, featuring an anniversary movie andsong, and more.
SITE MAP | TERUMO GLOBAL This page is the Terumo website Site Map. Business Overview. TIS Division (Terumo Interventional Systems) Neurovascular Division(MicroVention)
GLOBAL NETWORK
The regulatory approval status and availability of Terumo Group products differs by country and region.You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. HOSPITAL SYSTEMS DIVISION The Hospital Systems Division provides medical devices and pharmaceuticals that are used in a variety of medical settings, including ICUs, general wards, operating rooms, and patients' homes; along with training programs for medical professionals who use theproducts.
NORTH AMERICA
Japan; North America; South America; EMEA; Greater China; Asia; Terumo has been doing business in North America for nearly half a century. Terumo America Inc. (now Terumo Americas Holdings) was founded in 1971, and since then the Terumo business has grown much larger andmore diverse.
QUARTERLY RESULTS
"Terumo Information" for investors. Quarterly Results is available onthis page.
PRESENTATIONS
Presentation Material "Review on Performance in FY2016 and Mid- to Long-term Vision"(468.2 KB) "Financial Results for FYE 3/2017 and Guidance for FYE 3/2018"(555.4 KB) #02 CONTINUOUSLY INNOVATING FIRST-IN-CLASS TECHNOLOGY TO Reducing burden on patient blood during cardiovascular surgery by improving oxygenators. Terumo provides heart-lung machines that are used to circulate blood through the body in place of the heart during cardiovascular surgery, and hollow-fiber oxygenators that exchange oxygen for carbon dioxide in place of the lungs.GREATER CHINA
The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. TERUMO COMPLETES ACQUISITION OF CHINA-BASED ESSEN January 7, 2019. TOKYO, JAPAN - January 7, 2019 - Terumo Corporation (TSE: 4543) today announced that it completed its acquisition of Essen Technology (Beijing) Co., Ltd., a Chinese medical device company, onDecember 29, 2018.
TERUMO GLOBAL WEBSITESearch
*
About Terumo
About Terumo
* About Terumo Top
* Dear Stakeholders
* Terumo Group Identity * Terumo Group Code of Conduct* Corporate Profile
* Corporate Governance* Compliance
* Regulations and Standards * Directors and Executive Officers* History
* Procurement ActivityBack
*
Business Overview
Business Overview
* Business Overview Top * TIS Division(Terumo Interventional Systems) * Neurovascular Division (MicroVention)*
Cardiovascular Division * Cardiovascular Division * HeartSheet Division * Vascular Graft Division (Terumo Aortic) * Hospital Systems Division* Alliance Division
* Blood Management Company (Terumo BCT)Back
*
Technology
Technology
* Technology Top
*
Basic Information
* Basic Information Top * Research and Development * Production and Supply * Intellectual Property* Terumo Fellows
* Stories - Our TechnologiesBack
*
Sustainability
Sustainability
* Sustainability Top* News
* Message from Top Management * Sustainability at the Terumo Group * Resolving Healthcare Challenges * Creating a Diverse and Inclusive Workplace * Reducing Environmental Footprint * Serving Our Communities*
Sustainability Report * Sustainability Report Top* Back Numbers
* GRI Standards IndexBack
*
Investors
Investors
* Investors Top
*
Management Policy
* Management Policy Top * Top Management Message* IR Policy
* Business Risks
*
Financial Information * Financial Information Top* Quarterly Results
* Financial Highlights * Segment Information*
Shareholders & Stock * Shareholders & Stock Top* Stock Information
* Shareholder Return* Chart
* Credit Ratings and Corporate Bond* Analyst Coverage
* Shareholders Meeting * Articles of Incorporation*
IR Library
* IR Library Top
* Financial Statements* Presentations
*
Terumo Reports
* Terumo Reports Top* Back Numbers
* IR Events
* Mail for IR Inquiry* Disclaimer
Back
*
Our Stories
Our Stories
* Our Stories Top
Back
*
Newsroom
Newsroom
* 2020
* 2019
* 2018
* 2017
* 2016
* 2015
* 2014
* 2013
* 2012
* 2011
* 2010
Back
*
Global Network
Global Network
* Global Network Top* Japan
* North America
* South America
* Europe, Middle East and Africa* Greater China
* Asia and Pacific
Back
*
*
*
*
*
*
*
*
Terumo's Donation to Support COVID-19 Pandemic Relief Efforts Worldwide (April 22, 2020) Terumo's Response to COVID-19 PLEASE SELECT YOUR REGION Terumo Group provides products and services in over 160 countries and regions. Information about our products and services is available on regional and company-specific websites.* EMEA
* Greater China
* Asia
* Japan
* North America
* South America
TOPICS
*
Sustainability
Our efforts to make a meaningful difference for sustainable society*
Business Overview
Our seven business areas and main products*
Terumo Report 2019
For the fiscal year ended March 31, 2019 EU-MDR SAFETY AND PERFORMANCE INFORMATION Click here for safety and performance information on Terumo products required under the EU Medical Devices Regulation. Terumo Labeling WebsiteNEWSROOM
View all
*
May 14, 2020
Corporate
Terumo Appoints the Candidates for Directors*
May 5, 2020
Cardiac and Vascular Terumo Aortic Announces US FDA Approval for TREO Endovascular Device*
April 29, 2020
Cardiac and Vascular Terumo Aortic Announces US FDA Breakthrough Device Designation for Thoraflex™ Hybrid Device*
April 28, 2020
Cardiac and Vascular Terumo's BioPearl, the First Biodegradable Drug Eluting MicrospheresReceived CE mark
*
April 23, 2020
Blood Management
Terumo BCT's Mirasol Reduces the Virus Causing COVID-19 Below the Limit of Detection in Plasma and PlateletsWHAT'S NEW
View all
*
May 20, 2020
IR
Q&A regarding Financial Results for FYE 3/2020*
May 19, 2020
IR
Reference regarding Financial Results for FYE 3/2020*
May 19, 2020
IR
Audio webcast regarding Financial Results for FYE 3/2020*
May 18, 2020
IR
Presentation regarding Financial Results for FYE 3/2020*
May 18, 2020
IR
Financial Results for FYE 3/2020T
O
P
* Terms and Conditions of Use* Site Map
* Privacy Policy
* Social Media Policy Copyright (C) Terumo Corporation, All Rights Reserved.Disclaimer
Not all of the Terumo products shown on this website are registered in, approved for sale in, or available for purchase in, all countries or regions where this website is accessible. Please consult with your local Terumo representative, distributuion company or customer service center for additional information. Specific indications for use may also vary by country and region. Product images are provided for reference only.* Continue
* Back
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0